Citius Pharmaceuticals (CTXR) Competitors $1.29 +0.01 (+0.78%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+0.78%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. DRRX, CUE, LTRN, ICCC, HOWL, ANL, PYRGF, TELO, ABVC, and DTILShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include DURECT (DRRX), Cue Biopharma (CUE), Lantern Pharma (LTRN), ImmuCell (ICCC), Werewolf Therapeutics (HOWL), Adlai Nortye (ANL), PyroGenesis Canada (PYRGF), Telomir Pharmaceuticals (TELO), ABVC BioPharma (ABVC), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors DURECT Cue Biopharma Lantern Pharma ImmuCell Werewolf Therapeutics Adlai Nortye PyroGenesis Canada Telomir Pharmaceuticals ABVC BioPharma Precision BioSciences DURECT (NASDAQ:DRRX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Does the media favor DRRX or CTXR? In the previous week, DURECT had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for DURECT and 0 mentions for Citius Pharmaceuticals. DURECT's average media sentiment score of 0.22 beat Citius Pharmaceuticals' score of 0.00 indicating that DURECT is being referred to more favorably in the media. Company Overall Sentiment DURECT Neutral Citius Pharmaceuticals Neutral Do analysts recommend DRRX or CTXR? Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 4,008.53%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is DRRX or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to DURECT's net margin of -91.54%. Citius Pharmaceuticals' return on equity of -58.63% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-91.54% -267.36% -64.00% Citius Pharmaceuticals N/A -58.63%-37.67% Which has more risk & volatility, DRRX or CTXR? DURECT has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Which has better earnings and valuation, DRRX or CTXR? DURECT has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$2.03M28.75-$8.32M-$0.15-12.53Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Do institutionals and insiders believe in DRRX or CTXR? 28.0% of DURECT shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.2% of DURECT shares are held by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCitius Pharmaceuticals beats DURECT on 8 of the 13 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.61M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.18%P/E RatioN/A19.6629.8725.14Price / SalesN/A634.80422.9397.17Price / CashN/A165.0335.9458.58Price / Book0.134.198.105.59Net Income-$39.14M$31.61M$3.26B$265.48M7 Day PerformanceN/A0.95%0.64%1.22%1 Month Performance-33.16%2.90%2.42%0.39%1 Year Performance-94.20%4.11%27.60%23.47% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals1.9276 of 5 stars$1.29+0.8%$53.00+4,008.5%-94.3%$13.61MN/A0.0020Upcoming EarningsDRRXDURECT1.0291 of 5 stars$1.86+1.4%N/A+43.5%$57.73M$2.03M-12.4080Upcoming EarningsCUECue Biopharma3.8556 of 5 stars$0.76+3.4%$4.00+424.9%+19.1%$57.42M$7.99M-1.1460News CoverageUpcoming EarningsLTRNLantern Pharma2.274 of 5 stars$5.32+11.5%$25.00+369.9%+23.8%$57.38MN/A-2.8920News CoverageShort Interest ↑Gap UpHigh Trading VolumeICCCImmuCell0.0634 of 5 stars$6.24+4.0%N/A+63.7%$56.41M$26.49M-89.1370News CoverageUpcoming EarningsHOWLWerewolf Therapeutics3.9303 of 5 stars$1.24+6.9%$8.33+572.0%-31.0%$55.64M$1.14M-0.7440News CoverageUpcoming EarningsANLAdlai Nortye1.7505 of 5 stars$1.50+3.4%$9.00+500.0%-50.2%$55.35MN/A0.00127Gap UpPYRGFPyroGenesis Canada0.3452 of 5 stars$0.29+2.9%N/A-47.6%$54.55M$9.14M-4.8590TELOTelomir Pharmaceuticals2.9097 of 5 stars$1.83+4.0%$15.00+719.7%-58.0%$54.47MN/A-4.361News CoverageUpcoming EarningsABVCABVC BioPharma0.9754 of 5 stars$3.20+16.4%N/A+288.8%$54.34M$508.38K-24.6230Upcoming EarningsDTILPrecision BioSciences4.2302 of 5 stars$4.84+4.8%$47.00+871.1%-46.8%$53.67M$51.14M-2.41200News Coverage Related Companies and Tools Related Companies DRRX Competitors CUE Competitors LTRN Competitors ICCC Competitors HOWL Competitors ANL Competitors PYRGF Competitors TELO Competitors ABVC Competitors DTIL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts